13ᵗʰ International Symposium on Hodgkin Lymphoma
back to
back to
Program
Schedule
26.10.2024
27.10.2024
28.10.2024
Scientific Committee
Media
Photos
Videos
Downloads
Abstracts
Newsletters
Acknowledgements
Sponsors
Other Archives
ISHL13
ISHL12
Update on Hodgkin Lymphoma
ISHL11
ISHL10
ISHL9
ISHL8
ISHL7
Back to video list
Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826
Speaker
Sarah Rutherford
Session
Older Patients
Others Talks of this Session
Implementing Frailty Assessment for Treatment Guidance in HL
Optimal Use of Targeted Agents to Address Unmet Need in Older HL
A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent
Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023
Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial
This website uses cookies to ensure you get the best experience on our website. By using our site you agree to our use of cookies.
Learn more
Got it!